Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
Notes
Enhancement of Anticoagulant Effect of Warfarin Potassium Following Administration of Paclitaxel and Cisplatin
Fumiyoshi OjimaToshihiro ShidaMasayuki YamazawaYuta KatoShinya GotoTadashi Shiraishi
Author information
JOURNAL FREE ACCESS

2009 Volume 35 Issue 11 Pages 778-781

Details
Abstract
Warfarin potassium (Wf) interacts with a wide range of drugs and occasionally causes severe bleeding.We report the case of a 60-year-old female patient on Wf therapy who received 5 courses of cancer chemotherapy with doxorubicin,paclitaxel,and cisplatin.The Wf dose had to be reduced immediately after the chemotherapy due to an increase in international normalized ratio (INR).We then steadily increased the Wf dose till it had reached the previous level,which took almost 11 days from the time of receiving the anti-cancer agents.Although we could not determine which agent was interacting with Wf to cause the rise in INR in this case,we feel that attention must be paid to Wf drug-interactions for chemotherapy agents that have not previously been reported to interact with Wf in order to avoid the risk of bleeding.Therefore,there is a need for pharmacists to check medicines prescribed to patientsundergoingcancerchemotherapybyothermedicaldepart-ments and other medical clinics,especially for outpatients.
Content from these authors
© 2009 Japanese Society of Pharmaceutical Health Care and Sciences
Previous article Next article
feedback
Top